Dasa, former laboratory of Amil, paid 600 million R$ by SalomãoZoppi

The network of diagnostic medicine Dasa (Diagnostics), which belongs to the family, your Amil (now controlled by American United Health), announced the purchase of laboratory Diagnostic tests paulista SalomãoZoppi (SZD), founded by doctors Luis Vitor Solomon and Paulo Sérgio Zoppi in the years 1980. The value of the deal is valued at 600 million R$.
"The plans were attracting a financial investor to take the company to the stock exchange in 2018," said a source familiar with the matter. But it wasn''t just the funds began to harass the SDZ. Besides Dasa, other competitors such as Fleury and Hermes Pardini, also rated the triam active.
Concentrated in Sao Paulo, the SZD currently has 11 laboratory units in São Paulo and Grande São Paulo and was considered one of the most attractive assets for being a reference in the medical profession for its quality, as double checking tests. "The acquisition of this asset is important for Dasa, because the SalomãoZoppi is a benchmark in women''s tests," said another source familiar with the deal.
Heir. The negotiations for the purchase of the asset were conducted directly by Pedro Godoy Bueno, son of billionaire businessman Edson Bueno, who sold the Amil to United Health, for $10 billion in 2012. Former student of the financial market, Peter worked at Credit Suisse and BTG Pactual before assuming the Presidency of Dasa, to 24 years, in 2015.
The country''s largest diagnostic lab, with a turnover of 3.175 billion in 2015, R$ Dasa is present in 13 States of the country and in the Federal District, with more than 500 units. With about 30 of flags, including the Datta and Lavoisier (in São Paulo), Sergio Franco and PROGRAMMING (in Rio de Janeiro), the network should maintain the brand SalomãoZoppi, found the State.
The deal still depends on the approval of the Administrative Council for economic Defense (Cade). The law firm Mattos Filho advised the SalomãoZoppi and the Bueno family Lefosse.
From 2014, the Bueno family became controller and Dasa''s largest shareholder, to buy the company''s shares on the market. The company failed to negotiate their roles on the Novo Mercado of BM & FBovespa in 2015. The market expectation is that Dasa close their capital.
Consolidation. The medical diagnostic market has been the subject of consolidation and strong interest from foreign capital. One of the largest laboratories in the country, Paulo Fleury, had a portion of his business sold to the American Fund Advent.
Before the entry of the Fund, Fleury and the miner Hermes Pardini, who has the bottom Gávea as a major shareholder, rehearsed a merger, but the deal didn''t go ahead.
At the end of last year, the Alliar laboratory, the Country Investments, was the only company to go to the stock market in 2016. Now is the time of the Hermes Pardini, which will go public in early February (read more on page B7).
"The healthcare industry as a whole is one of the most attracting investors," said a market source. In addition, diagnostic labs are acquisition targets health plan providers, hospitals and pharmaceutical industries.